Realtime | Geld | Brief | Zeit |
---|---|---|---|
11,800 | 12,400 | 22:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 4 | Investing.com Deutsch | ||
14.07. | William Blair stuft MiNK-Therapeutics-Aktie nach 700-%-Rallye herab | 8 | Investing.com Deutsch | ||
14.07. | William Blair downgrades MiNK Therapeutics stock to Market Perform after 700% surge | 3 | Investing.com | ||
MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.07. | MiNK Therapeutics stock maintains Buy rating at H.C. Wainwright after case study publication | 1 | Investing.com | ||
14.07. | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
14.07. | MiNK Therapeutics stock falls after William Blair downgrade | 4 | Investing.com | ||
14.07. | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 274 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
11.07. | Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? | 11 | Benzinga.com | ||
11.07. | MiNK Therapeutics Stock Skyrockets 643% On Cancer Remission Case | 4 | RTTNews | ||
11.07. | Durchbruch in der Krebstherapie: Aktie von MiNK Therapeutics schießt um 200 % in die Höhe | 47 | Investing.com Deutsch | ||
11.07. | MiNK Therapeutics stock soars after cancer remission breakthrough | 8 | Investing.com | ||
11.07. | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer | 101 | GlobeNewswire (Europe) | NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen | |
18.06. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.06. | MiNK Therapeutics Announces Virtual Annual Shareholders Meeting | 1 | GlobeNewswire (USA) | ||
02.06. | MiNK Therapeutics receives NIH grant for GvHD therapy | 2 | Investing.com | ||
02.06. | MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients | 37 | GlobeNewswire (Europe) | NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BB BIOTECH | 32,950 | -0,60 % | Aktien KW 30 - Weg erst durch EU-US-Zolleinigung frei? Warten bis zum 1. August? Oder TACO? Bis dahin Einzelwerte im Fokus. News. Evotec. Almonty. Heidelberger Druck. ThyssenKrupp nucera. HELLA. Palfinger. BB Biotech. Sartorius. Berentzen. GFT. STEYR Moto | Aktien: Diese Woche Einzelwerte mit Zahlen im Fokus - Berichtssaison lässt grüssen. Puma bricht ein, Evotec nach unten durchgereicht. Aber auch das: Deutsche Bank zweistelliger Kurssprung. Und so setzte... ► Artikel lesen | |
VIKING THERAPEUTICS | 34,200 | +3,89 % | Doppelschlag mit Viking Therapeutics und Rheinmetall | An der Börse gibt es Momente, in denen wenige Tage über den Erfolg einer ganzen Strategie entscheiden. Wer solche Chancen erkennt und entschlossen handelt, kann in kurzer Zeit außergewöhnliche Ergebnisse... ► Artikel lesen | |
NOVOCURE | 9,616 | +2,28 % | Novocure Reports Second Quarter 2025 Financial Results | Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual... ► Artikel lesen | |
OXFORD NANOPORE TECHNOLOGIES | 2,510 | +3,29 % | Oxford Nanopore Technologies: ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology | New adventitious viral agent (AVA) detection test offers rapid, sensitive, and affordable viral screening for biomanufacturers
ViruSure, a global leader in pathogen safety testing for biopharmaceuticals... ► Artikel lesen | |
MEREO BIOPHARMA | 1,300 | -0,38 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
ASSERTIO | 0,829 | +14,06 % | Assertio narrows 2025 sales guidance to $108M-$118M as transformation accelerates | ||
ROIVANT SCIENCES | 9,860 | +2,39 % | Roivant Sciences: Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update | BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a... ► Artikel lesen | |
APPLIED THERAPEUTICS | 0,379 | -1,28 % | Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting | Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute... ► Artikel lesen | |
AKERO THERAPEUTICS | 41,370 | -3,97 % | Akero Therapeutics Inc.: Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant... ► Artikel lesen | |
ARVINAS | 6,800 | +3,26 % | Arvinas Inc.: Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | - Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant - -... ► Artikel lesen | |
REVOLUTION MEDICINES | 29,800 | -0,67 % | Revolution Medicines, Inc.: Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress | Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough... ► Artikel lesen | |
JANUX THERAPEUTICS | 24,270 | +7,20 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
WEREWOLF THERAPEUTICS | 1,185 | +2,60 % | Werewolf Therapeutics celebrates 'Full Moon Moments' in clinical trial recruitment push | ||
TRANSCODE THERAPEUTICS | 11,505 | +8,33 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen |